1352246-47-9

Upstream product

• 934989-24-9 benzyl (1R,2R,4S)-4-(tert-butoxycarbonyl(methyl)amino)-2-(2,4-difluorophenyl)-cyclopentanecarboxylate 

Downstream Products

• 1352244-99-5 [4-[2-(4-chloro-3-methyl-phenyl)-5-methyl-1,2,4-triazol-3-yl]-1-piperidyl]-[(1R,2R,4S)-2-(2,4-difluorophenyl)-4-(methyl(3,3,3-trifluoropropyl)amino)cyclopentyl]methanone trifluoroacetate 
• 1352244-97-3 [4-[2-[4-chloro-3-methyl-phenyl]-5-methyl-1,2,4-triazol-3-yl]-1-piperidyl]-[(1R,2R)-2-(2,4-difluorophenyl)-4-methylamino-cyclopentyl]methanone trifluoroacetate 
• 1352246-48-0 tert-butyl N-[(1S,3R,4R)-3-[4-[2-(4-chloro-3-methyl-phenyl)-5-methyl-1,2,4-triazol-3-yl]piperidine-carbonyl]-4-(2,4-difluorophenyl)cyclopentyl]-N-methyl-carbamate 

Relevant academic research and scientific papers

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.